v3.26.1
Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)
 2 Months Ended 3 Months Ended 6 Months Ended
Oct. 31, 2025
agreement
Jun. 30, 2026
USD ($)
Mar. 31, 2026
USD ($)
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Jun. 30, 2026
USD ($)
segment
Jun. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Deferred grant funding   $ 14,954,724       $ 14,954,724   $ 19,651,452
Cash and cash equivalents   12,617,594   $ 5,035,006   12,617,594 $ 5,035,006 24,711,356
Working capital   200,000       200,000    
Accumulated deficit   194,671,566       194,671,566   188,688,904
Net loss   2,982,773 $ 2,999,889 4,016,483 $ 4,378,307 5,982,662 8,394,790  
Cash flow from operations           $ 12,300,000    
Number of operating segments | segment           1    
Number of reportable segments | segment           1    
Total revenue   187,546       $ 340,001 4,255  
Outstanding advances   2,100,000       2,100,000    
Other receivables               $ 400,000
Restricted cash included in other non-current assets   300,000   $ 300,000   300,000 $ 300,000  
Location, Statement of Financial Position, Balance [Axis]: us-gaap:OtherAssetsCurrent                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Outstanding advances   400,000       400,000    
Location, Statement of Financial Position, Balance [Axis]: us-gaap:OtherAssetsNoncurrent                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Outstanding advances   $ 1,700,000       1,700,000    
Preeclampsia Agreement                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Number of services agreements | agreement 2              
Total revenue           499,000    
Contraceptive Landscape Review Agreement                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Transaction price allocated to remaining performance obligations           300,000    
Research And Development Services                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Total revenue           $ 400,000    
Minimum                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Indirect cost allowance percentage   5.00%       5.00%    
Repayment period on outstanding advances           2 years    
Maximum                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Indirect cost allowance percentage   22.00%       22.00%    
Repayment period on outstanding advances           4 years